Macular Therapeutics, Inc. today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,096,993, U.S. Patent No. 11,123,411 U.S. Patent No. 11,123,412 each entitled “Method of Treating Macular Degeneration Using Botulinum-Based Neuromodulators.
BOSTON--(BUSINESS WIRE)-- Macular Therapeutics, Inc., (MCT) a private biotechnology company targeting neuromodulation and molecular-guided tissue remodeling to stabilize cellular barriers and tissue structures in the eye, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,096,993, U.S. Patent No. 11,123,411 U.S. Patent No. 11,123,412 each entitled “Method of Treating Macular Degeneration Using Botulinum-Based Pharmaceuticals.”
These three patents cover neuromodulator-based methods for: (1) treating and retarding the progression of dry macular degeneration wherein the drug product is injected into the para orbital region outside the eye or eye region and target anatomic structures inside the eye: (2) increasing the potency and duration of action of anti-VEGF agents effect on intra retinal edema; and (3) treating and slowing the development of macular degeneration and preserving the choriocapillaris, retinal pigment epithelium, and long-term function of other anatomic structures inside the eye.
“The issuance of these three foundational patents targeting macular degeneration has strengthened MCT’s intellectual property estate and provided us with a proprietary therapeutic blueprint to enable a robust clinical development pipeline of botulinum-based neuromodulator compositions and unique delivery approaches to enhance safety and tolerability in treating macular degeneration and other serious ocular diseases,” said Gary Borodic, MD, President of Macular Therapeutics, Inc.
About Macular Therapeutics, Inc.
Macular Therapeutics Inc. is a private, clinical-stage biotech company targeting neuromodulation and molecular-guided tissue remodeling to stabilize cellular barriers and tissue structures inside the eye to reduce the prevalence and treatment frequency from macular degeneration, the leading causes of irreversible blindness in the developed world. The MCT team is committed to developing transformative botulinum neuromodulation drug products and highly tolerable, non-intravitreal approaches to deliver neuromodulators to the back of the eye to address the current major unmet medical needs in serious and rare ocular diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211130005143/en/
Contacts
Inquiries
Macular Therapeutics, Inc.
Gary Borodic, M.D.
Phone: +1 (617) 770-0011 and +1 (617) 270-7949
Email: gborodic@maculartherapeutics.com; dbrowne@maculartherapeutics.com
Source: Macular Therapeutics, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20211130005143/en
